BioNexus Gene Lab (NASDAQ:BGLC), trading on NASDAQ under the symbol BGLC, is a molecular diagnostics and genomics company specializing in next-generation sequencing, gene expression profiling, and personalized medicine solutions. Established in 2005 as a spin-off from a leading research university, BioNexus has built a comprehensive platform combining laboratory services, proprietary assay development, and bioinformatics tools to support clinical and translational research. The company operates a CLIA-certified, CAP-accredited laboratory in the United States and maintains strategic partnerships with academic medical centers and biotechnology firms worldwide.
The company’s core services include high-throughput sequencing, targeted gene panels for oncology and rare diseases, and custom assay design. BioNexus also provides end-to-end project management for biomarker discovery, validation studies, and companion diagnostic development. In recent years, BioNexus expanded its product portfolio to include liquid biopsy analyses for circulating tumor DNA detection, as well as RNA-based fusion and expression panels. These offerings are supported by a proprietary bioinformatics pipeline that enables data integration, variant annotation, and actionable reporting for clinicians and research teams.
BioNexus serves a diverse client base across North America, Europe, and Asia, including pharmaceutical companies conducting clinical trials, academic institutions pursuing translational research, and hospital systems integrating molecular testing into patient care. The company’s global reach is underpinned by regional offices in London and Singapore, facilitating regulatory support, sample logistics, and local customer engagement. BioNexus’s collaborations with key opinion leaders and research consortia help drive innovation in precision oncology, immunogenomics, and rare disease diagnostics.
Leadership at BioNexus Gene Lab is headed by Chief Executive Officer Dr. Jonathan Park, whose background spans molecular biology and clinical diagnostics. Chief Scientific Officer Dr. Anna Lee guides the company’s research and development efforts, while Chief Financial Officer Mary Johnson oversees strategic financial planning and corporate governance. Together, the management team focuses on expanding BioNexus’s service capabilities, forging strategic partnerships, and advancing the adoption of genomic insights in healthcare delivery.
